Clinical Section Chief of Biochemistry in South Sector at Alberta Precision Laboratories (APL); Clinical Professor of Pathology and Laboratory Medicine (DPLM) at the University of Calgary
Biography
He received his graduate degrees (MS and PhD) from the University of Minnesota in Minneapolis and continued his postgraduate training in Clinical Chemistry at the University of Washington in Seattle. Certified in Clinical Chemistry by the American Board of Clinical Chemistry and the National Registry in Clinical Chemistry, Dr. Sadrzadeh has directed clinical chemistry and toxicology laboratories at different institutions such as Harvard Medical School, the University of Arizona, and the University of Washington in Seattle, Cedars Sinai Medical Center and APL for over 25 years. Also, as a director of graduate and postdoctoral fellowship programs, he has devoted most of his academic life to medical education and has trained over 65 clinical chemistry fellows, residents, graduate and undergraduate students.
Dr. Sadrzadeh is a widely recognized clinical chemist and scientist who has authored over 220 peer reviewed articles, book chapters, monographs, abstracts, and co-edited a book. His research interests have been mostly focused on the role of iron, hemoglobin and haptoglobin in initiating or modulating oxidative stress and tissue injury in neurodegenerative and metabolic disorders. He has been funded by NIH, JDRF and several other funding agencies in the US and Canada. He has been an invited speaker at regional, national and international venues.
Dr. Sadrzadeh also directs clinical projects aimed at developing new markers and methods using LC-MS/MS technology. He has successfully implemented LC-MS/MS systems in different clinical laboratories in the past 20 years.
Dr. Sadrzadeh is a widely recognized clinical chemist and scientist who has authored over 220 peer reviewed articles, book chapters, monographs, abstracts, and co-edited a book. His research interests have been mostly focused on the role of iron, hemoglobin and haptoglobin in initiating or modulating oxidative stress and tissue injury in neurodegenerative and metabolic disorders. He has been funded by NIH, JDRF and several other funding agencies in the US and Canada. He has been an invited speaker at regional, national and international venues.
Dr. Sadrzadeh also directs clinical projects aimed at developing new markers and methods using LC-MS/MS technology. He has successfully implemented LC-MS/MS systems in different clinical laboratories in the past 20 years.
